Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 ... PharmiWeb.com (press release) MONROVIA Calif. April 10 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR) a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases asthma and allergic diseases and cancer ... Xencor Reports Fourth Quarter and Full Year 2013 Financial Results Xencor Gets Milestone Payment From Merck |
